Apollo Global Management is planning to bid on GSK's entire portfolio of drugs

  • GSK,GlaxoSmithKline,Apollo

GlaxoSmithKline ($GSK) has long explored a sale of some $3 billion worth of its older drugs, planning to shed products by geographic region to meet buyers' interests. Now, the company could have a more enticing offer on its hands as private equity firm Apollo Global Management is planning to bid on GSK's entire portfolio of drugs, people familiar with the process toldReuters.

Last month, sources told Reuters that GSK would begin to take bids for aging products in November and that the company would hive off drugs by geographical region, reflecting the needs of buyers. Potential suitors such Denmark's Lundbeck and India's Lupin are both looking to expand in the U.S. and are also preparing for patent losses some of their top-selling products. GSK brands up for sale include the antidepressant Paxil, migraine treatment Imitrex, stomach acid-reducer Zantac and nausea fighter Zofran--drugs expected to have combined 2014 sales of around ?1 billion ($1.6 billion) but face competition from cheap generics.

As part of the deal, GSK would hold onto rights for the drugs in emerging markets, where demand for the products is still growing.

This is not the first time private equity has weighed a buyout of Big Pharma's aging meds. In August, KKR, Warburg Pincus, Blackstone Capital, Bain Capital and Apollo were also said to be eyeing GSK's and Novartis' older drugs, planning to merge the two company's portfolios into one bigger set.

Meanwhile, GSK is waiting to complete its three-part deal to sell and combine assets with Novartis ($NVS). In April, the company engineered a $20 million asset swap with the Swiss drugmaker, handing its oncology business to Novartis, snatching up the latter's vaccines unit and setting up a consumer health joint venture to market over-the-counter products with an estimated $11 billion in sales. Novartis and GSK expect to close the multipart deal sometime early next year, the companies said when the asset swap was announced.

GSK is not the only drugmaker looking to unload aging products. Abbott Laboratories ($ABT) recently sold off many of its older drugs to Mylan ($MYL) in a $5.3 billion deal, and in September AstraZeneca ($AZN) passed off 18 aging meds to specialty generics maker IGI Laboratories for $500,000 up front, plus $6 million in milestones and up to $3 million in royalties. Merck ($MRK) and Sanofi ($SNY) are also shopping around portfolios, but Sanofi's plans have stalled as top company managers could not agree on how to move forward with the sale.

This link:http://www.chemcd.com/news/7722.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus


Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.